Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sitagliptin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses. |
| Sitagliptin | ACTIVE_COMPARATOR | Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses. |
| Taspoglutide 10 mg | EXPERIMENTAL | Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses. |
| Taspoglutide up-titrated to 20 mg | EXPERIMENTAL | Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses. |
| Name | Type | Description |
|---|---|---|
| Metformin | DRUG | As prescribed |
| Placebo (matching sitagliptin) | DRUG | Once daily oral administration of placebo (matching sitagliptin). |
| Placebo (matching taspoglutide) | DRUG | Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide). |
| Sitagliptin | DRUG | Once daily oral administration of 100 mg of sitagliptin. |
| Taspoglutide | DRUG | Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide. |
Inclusion Criteria: * adult patients, 18-75 years of age; * type 2 diabetes receiving metformin (\>=1500mg/day) for at least 12 weeks; * HbA1c \>=7.0% and \<=10.0% at screening; * BMI \>=25 (\>23 for Asians) and \<=45kg/m2 at screening; * stable weight +/- 5% for at least 12 weeks prior to screenin...
Sitagliptin is used for the treatment of Type 2 Diabetes Mellitus. It is being studied in patients whose condition is inadequately controlled with metformin. The drug is in Phase 3 clinical development and is being developed by Roche Holding AG.
Sitagliptin is a small molecule developed for Type 2 Diabetes Mellitus. Its specific molecular target is not disclosed in the available information. The drug is being evaluated in a Phase 3 clinical trial for its efficacy and safety in this patient population.
Sitagliptin is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 3 clinical trial of the drug for the treatment of Type 2 Diabetes Mellitus.
Sitagliptin is in Phase 3 clinical development. It is an investigational drug for Type 2 Diabetes Mellitus and has not been approved by regulatory authorities. The Phase 3 trial has been completed, with 666 participants enrolled.
Sitagliptin has one completed Phase 3 clinical trial registered under NCT00754988. The study, titled "A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin," enrolled 666 participants across multiple countries.
Sitagliptin is not the same as Taspoglutide. In the clinical trial NCT00754988, Taspoglutide is the investigational drug being compared against Sitagliptin as an active comparator. Sitagliptin is a separate drug developed by Roche Holding AG for Type 2 Diabetes Mellitus.